Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October

Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October


A mid-stage clinical success wasn't encouraging enough to lift the stock amid overall negative sentiment surrounding the biotech industry. Leaked emails highlighting the Clinton campaign's intentions to criticize drugmakers in order to distinguish her candidacy was a heavy weight on biotech stocks last month.



from Biotech News